Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

REGN Regeneron Pharmaceuticals

Market Closed 05-17 16:00:00 EDT

982.29

+14.31

+1.48%

盘后982.29

+0.000.00%

18:19 EDT

High982.77	Low966.00	Vol386.56K
Open969.27	D1 Closing967.98	Amplitude1.73%
Mkt Cap108.23B	Tradable Cap104.12B	Total Shares110.19M
T/O377.96M	T/O Rate0.36%	Tradable Shares106.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"REGN","market":"US","secType":"STK","nameCN":"Regeneron Pharmaceuticals","latestPrice":982.29,"timestamp":1715976000000,"preClose":967.98,"halted":0,"volume":386559,"hourTrading":{"tag":"盘后","latestPrice":982.29,"preClose":982.29,"latestTime":"18:19 EDT","volume":10638,"amount":10449593.08,"timestamp":1715984364986},"delay":0,"floatShares":106000000,"shares":110185503,"eps":33.84642,"marketStatus":"Market Closed","change":14.31,"latestTime":"05-17 16:00:00 EDT","open":969.27,"high":982.77,"low":966,"amount":377960690.8512,"amplitude":0.017325,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":33.84642,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1716192000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":967.98,"preHourTrading":{"tag":"盘前","latestPrice":968,"preClose":967.98,"latestTime":"09:29 EDT","volume":451,"amount":436497.9597,"timestamp":1715952599978},"postHourTrading":{"tag":"盘后","latestPrice":982.29,"preClose":982.29,"latestTime":"18:19 EDT","volume":10638,"amount":10449593.08,"timestamp":1715984364986},"volumeRatio":0.9938159028767727,"overnightSupported":true},"requestUrl":"/m/hq/s/REGN/wiki","defaultTab":"wiki","newsList":[{"id":"2436918085","title":"Novo Nordisk, J&J lead R&D rankings in big pharma: report","url":"https://stock-news.laohu8.com/highlight/detail?id=2436918085","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2436918085?lang=en_us&edition=fundamental","pubTime":"2024-05-19 02:52","pubTimestamp":1716058327,"startTime":"0","endTime":"0","summary":"Weight loss drugmaker Novo Nordisk (NVO) (OTCPK:NONOF) and U.S. healthcare giant Johnson & Johnson (NYSE:JNJ) have become the most transformative companies in big pharma, according to a new report bas","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1461608537/image_1461608537.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1461608537/image_1461608537.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4108110-novo-nordisk-j-j-lead-rd-big-pharma","is_publish_highlight":false,"gpt_icon":0},{"id":"2436189468","title":"Roche Is Joining The Obesity Party But Questions Remain","url":"https://stock-news.laohu8.com/highlight/detail?id=2436189468","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2436189468?lang=en_us&edition=fundamental","pubTime":"2024-05-18 23:18","pubTimestamp":1716045533,"startTime":"0","endTime":"0","summary":"Roche's obesity candidate CT-388 showed positive results in a phase 1b trial, with an 18.8% placebo-adjusted weight loss at week 24.The full data presentation is needed to assess safety and tolerabili","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1767278670/image_1767278670.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1767278670/image_1767278670.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4694321-roche-is-joining-the-obesity-party-but-questions-remain","is_publish_highlight":false,"gpt_icon":0},{"id":"2436415219","title":"Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point","url":"https://stock-news.laohu8.com/highlight/detail?id=2436415219","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2436415219?lang=en_us&edition=fundamental","pubTime":"2024-05-17 22:44","pubTimestamp":1715957045,"startTime":"0","endTime":"0","summary":"The latest period was a rollercoaster ride for Arrowhead Pharmaceuticals despite significant fundamental developments.Phase 3 results of plozasiran in FCS patients should lead to Arrowhead finally bec","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1211364640/image_1211364640.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1211364640/image_1211364640.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4694100-arrowhead-pharmaceuticals-focus-turns-to-upcoming-pipeline-inflection-point","is_publish_highlight":false,"gpt_icon":0},{"id":"2436948479","title":"Regeneron wins temporary restraining order preventing Eylea generic launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2436948479","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2436948479?lang=en_us&edition=fundamental","pubTime":"2024-05-17 22:01","pubTimestamp":1715954494,"startTime":"0","endTime":"0","summary":"Regeneron (NASDAQ:REGN) won a temporary restraining order that blocks drugmakers including, Mylan Pharmaceuticals/Biocon Biologics, from launching a generic version of its blockbuster eye drug Eylea. ","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1399246824/image_1399246824.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1399246824/image_1399246824.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4107951-regeneron-wins-temporary-restraining-order-preventing-eylea-generics","is_publish_highlight":false,"gpt_icon":0},{"id":"2436994731","title":"BUZZ-Brokerages await lung disease drug data from Amgen","url":"https://stock-news.laohu8.com/highlight/detail?id=2436994731","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2436994731?lang=en_us&edition=fundamental","pubTime":"2024-05-17 18:35","pubTimestamp":1715942129,"startTime":"0","endTime":"0","summary":"** Brokerages await trial data presentations from Amgen  and Regeneron    on Sunday as both companies vie for market share with their experimental treatments for chronic obstructive pulmonary disease    ** BMO Capital Markets believes investors will focus on how AMGN's drug Tezspire compares to REGN's Dupixent in COPD patients with high count of a type of white blood cell called eosinophil   ** J.P.Morgan says Tezspire's mid-stage data looks \"interesting\" in the high eosinophil patient population as the drug showed 37% reduction in COPD exacerbation compared to 30% and 34% reductions seen in Dupixent late-stage trials    ** However, the brokerage feels Dupixent will be well established with a \"first to market advantage, a high bar set on efficacy and very broad/favorable payer coverage\"    ** The U.S. FDA is expected to take a decision on Dupixent's use for the treatment of COPD by June 27   ** COPD is a common lung disease causing restricted airflow and breathing problems   ** Up to l","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2436778941","title":"More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2436778941","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2436778941?lang=en_us&edition=fundamental","pubTime":"2024-05-17 17:45","pubTimestamp":1715939100,"startTime":"0","endTime":"0","summary":"Grace Sun, 16, receives $75,000 Top Award for a new kind of organic electrochemical transistor at the world’s largest pre-college science, technology, engineering and math (STEM) competition.TARRYTOWN","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/17/2884439/0/en/More-than-9-Million-Awarded-to-High-School-Scientists-and-Engineers-at-the-Regeneron-International-Science-and-Engineering-Fair-2024.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435672114","title":"AbCellera: If You Build It, Will They Come? Fresh Impetus Required","url":"https://stock-news.laohu8.com/highlight/detail?id=2435672114","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2435672114?lang=en_us&edition=fundamental","pubTime":"2024-05-16 20:39","pubTimestamp":1715863140,"startTime":"0","endTime":"0","summary":"AbCellera's valuation has shrunk by 80% since its IPO due to the withdrawal of its COVID antiviral, bamlanivimab.The company reported Q1 2024 revenues of $10 million, down from $12.2 million in the pr","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1501249755/image_1501249755.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1501249755/image_1501249755.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4693825-abcellera-if-you-build-it-will-they-come-fresh-impetus-required-abcl-stock","is_publish_highlight":false,"gpt_icon":0},{"id":"1175166587","title":"Top Calls on Wall Street: Tesla, Nvidia, Roblox, Western Digital, Boston Beer and More","url":"https://stock-news.laohu8.com/highlight/detail?id=1175166587","media":"Tiger Newspress","top":-1,"share":"https://ttm.financial/m/news/1175166587?lang=en_us&edition=fundamental","pubTime":"2024-05-14 23:30","pubTimestamp":1715700600,"startTime":"0","endTime":"0","summary":"Here are the biggest calls on Wall Street on Tuesday:Tesla outlook is murky after earnings, Barclays saysTesla’s first-quarter earnings report suggests uncertainty ahead for the electric vehicle maker","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"gpt_icon":1},{"id":"2435929510","title":"Evercore says biotech ‘winter is finally thawing’","url":"https://stock-news.laohu8.com/highlight/detail?id=2435929510","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2435929510?lang=en_us&edition=fundamental","pubTime":"2024-05-14 23:24","pubTimestamp":1715700272,"startTime":"0","endTime":"0","summary":"Evercore ISI launched its coverage with a bullish view on a number of biotech stocks on Tuesday, citing a more constructive view on the sector, which is seeing signs of recovery after years of underpe","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1651064790/image_1651064790.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1651064790/image_1651064790.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4105937-evercore-says-biotech-winter-is-finally-thawing","is_publish_highlight":false,"gpt_icon":0},{"id":"2435937212","title":"Sanofi (SNY), Regeneron's Dupixent sBLA Gets FDA Priority Tag","url":"https://stock-news.laohu8.com/highlight/detail?id=2435937212","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2435937212?lang=en_us&edition=fundamental","pubTime":"2024-05-13 22:25","pubTimestamp":1715610300,"startTime":"0","endTime":"0","summary":"Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their supplemental biologics license application  seeking approval for the blockbuster medicine Dupixent for adolescents with inadequately controlled chronic rhinosinusitis with nasal polyposis . These children should be aged between 12 to 17 years. Given the priority review of the sBLA, the FDA is expected to give its decision on Sep 15.If approved by the FDA, Dupixent will be the first medicine approved for adolescents with this disease, which is driven in part by underlying type II inflammation that obstructs the sinuses and nasal passages and can result in loss of sense of smell.Dupixent is already approved in the United States for treating CRSwNP in adults. The sBLA is based on extrapolation of efficacy data from two pivotal CRSwNP studies on Dupixent in adults as well as safety data of Dupixent in its currently approved indications for adolescents like moderate-to-severe eczema .Sanofi stock has declined 0.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/1H9NqoSNLfLtMd2fyMlfBA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/1H9NqoSNLfLtMd2fyMlfBA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sanofi-sny-regenerons-dupixent-sbla-142500450.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435405763","title":"Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Younger CRSwNP Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2435405763","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2435405763?lang=en_us&edition=fundamental","pubTime":"2024-05-13 18:09","pubTimestamp":1715594940,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals and Sanofi have won Food and Drug Administration priority review of their application seeking expanded approval of their blockbuster anti-inflammatory drug Dupixent for adolescents with a sinus condition that can lead to a loss of the sense of smell.Regeneron and Sanofi on Monday said the application covers Dupixent as an add-on maintenance treatment for patients ages 12 to 17 with inadequately controlled chronic rhinosinusitis with nasal polyposis, or CRSwNP.The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period. The agency has set a target action date of Sept. 15 for the application.Regeneron and Sanofi said an FDA green light would make Dupixent the first treatment in the U.S. for those ages 12 to 17 with inadequately controlled CRSwNP, which is driven in part by an underlying type 2 inflammation that obstructs the sinuses a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2435019313","title":"BRIEF-Regeneron Dupixent SBLA Accepted For FDA Priority Review For Treatment Of Adolescents With CRSWNP","url":"https://stock-news.laohu8.com/highlight/detail?id=2435019313","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2435019313?lang=en_us&edition=fundamental","pubTime":"2024-05-13 13:18","pubTimestamp":1715577534,"startTime":"0","endTime":"0","summary":"May 13  - Regeneron Pharmaceuticals Inc :   * DUPIXENT  SBLA ACCEPTED FOR FDA PRIORITY REVIEW FOR TREATMENT OF ADOLESCENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS    * TARGET ACTION DATE FOR FDA DECISION IS SEPTEMBER 15, 2024   * REGENERON - SAFETY RESULTS IN BOTH SINUS-24 AND SINUS-52 WERE GENERALLY CONSISTENT WITH KNOWN SAFETY PROFILE OF DUPIXENT IN APPROVED INDICATIONSSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2434335236","title":"What Makes Viking Therapeutics An Attractive Takeover Target Or Big Pharma Partner","url":"https://stock-news.laohu8.com/highlight/detail?id=2434335236","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2434335236?lang=en_us&edition=fundamental","pubTime":"2024-05-12 17:43","pubTimestamp":1715507013,"startTime":"0","endTime":"0","summary":"Viking Therapeutics' subcutaneously administered version of VK2735 has generated competitive data in the phase 2 trial in obese patients.The oral formulation of VK2735 reported good tolerability that ","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1464497061/image_1464497061.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1464497061/image_1464497061.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4692515-what-makes-viking-therapeutics-an-attractive-takeover-target-or-big-pharma-partner","is_publish_highlight":false,"gpt_icon":0},{"id":"2434828982","title":"HQH: Future Rate Cuts Will Help Fund's Performance","url":"https://stock-news.laohu8.com/highlight/detail?id=2434828982","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2434828982?lang=en_us&edition=fundamental","pubTime":"2024-05-11 16:55","pubTimestamp":1715417702,"startTime":"0","endTime":"0","summary":"Trevor Williams/DigitalVision via Getty Images Overview The healthcare sector's (XLV) performance continues to lag behind that of the S&P 500 (SPY). This can be attributed to a variety of things, such","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1635107530/image_1635107530.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1635107530/image_1635107530.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4692155-hqh-future-rate-cuts-will-help-funds-performance","is_publish_highlight":false,"gpt_icon":0},{"id":"2434830168","title":"Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) large institutional owners must be happy as stock continues to impress, up 3.2% over the past week","url":"https://stock-news.laohu8.com/highlight/detail?id=2434830168","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2434830168?lang=en_us&edition=fundamental","pubTime":"2024-05-10 19:00","pubTimestamp":1715338810,"startTime":"0","endTime":"0","summary":"Institutions' substantial holdings in Regeneron Pharmaceuticals implies that they have significant influence over the company's share price. A total of 10 investors have a majority stake in the company with 51% ownership. If you want to know who really controls Regeneron Pharmaceuticals, Inc. , then you'll have to look at the makeup of its share registry. With 85% stake, institutions possess the maximum shares in the company. In other words, the group stands to gain the most  from their investment into the company.And things are looking up for institutional investors after the company gained US$3.3b in market cap last week. One-year return to shareholders is currently 30% and last week’s gain was the icing on the cake.Let's take a closer look to see what the different types of shareholders can tell us about Regeneron Pharmaceuticals.Check out our latest analysis for Regeneron Pharmaceuticals. What Does The Institutional Ownership Tell Us About Regeneron Pharmaceuticals?While studying i","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/regeneron-pharmaceuticals-inc-nasdaq-regn-110010355.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434836555","title":"Merck: The Worst Has Been Avoided (Rating Upgrade)","url":"https://stock-news.laohu8.com/highlight/detail?id=2434836555","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2434836555?lang=en_us&edition=fundamental","pubTime":"2024-05-10 18:02","pubTimestamp":1715335361,"startTime":"0","endTime":"0","summary":"On April 25, one of the leaders in the global oncology drugs market published extremely positive financial results for the first quarter of 2024.Keytruda sales were about $6.95 billion in the first qu","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1337117159/image_1337117159.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1337117159/image_1337117159.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4691766-merck-stock-q1-earnings-worst-has-been-avoided-rating-upgrade-buy","is_publish_highlight":false,"gpt_icon":0},{"id":"2434300611","title":"Q1 2024 Intellia Therapeutics Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2434300611","media":"Thomson Reuters StreetEvents","top":-1,"share":"https://ttm.financial/m/news/2434300611?lang=en_us&edition=fundamental","pubTime":"2024-05-10 11:53","pubTimestamp":1715313196,"startTime":"0","endTime":"0","summary":"Ian Karp; Head-IR & Corporate Communications; Intellia Therapeutics Inc.John Leonard; President, Chief Executive Officer, Director; Intellia Therapeutics Inc. David Lebwohl; Executive Vice President, Chief Medical Officer; Intellia Therapeutics Inc. Laura Sepp-Lorenzino; Executive Vice President, Chief Scientific Officer; Intellia Therapeutics Inc. Good morning, and welcome to Intellia Therapeutics First Quarter 2024 financial results conference call. My name is Drew, and I will be your conference operator today. Following formal remarks, we will open the call up for a question and answer session. This conference is being recorded at the company's request and will be available on the company's website following the end of the call.  I will now turn the conference over to Ian Karp, Senior Vice President of Investor Relations and Corporate Communications at Intellia. Please proceed.Thank you, Ian and good morning, everyone, and thank you all for joining us today. We've made outstanding p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q1-2024-intellia-therapeutics-inc-035316127.html","is_publish_highlight":false,"gpt_icon":1},{"id":"2434098361","title":"Three overlooked stocks from a Spanish quant: 'Now is not a time everyone is going to win.'","url":"https://stock-news.laohu8.com/highlight/detail?id=2434098361","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2434098361?lang=en_us&edition=fundamental","pubTime":"2024-05-09 18:50","pubTimestamp":1715251800,"startTime":"0","endTime":"0","summary":"With the S&P 500 SPX up more than 8% so far this year, the challenge is on for stock pickers around the world to find those overlooked companies.\"We believe now is not a time everyone's going to win and that now, stock selection is becoming more and more important,\" Madrid-based Nicole Sophie Gómez Adenis, U.S. equities and multi-asset portfolio manager at Mapfre Asset Management, tells MarketWatch in an interview.\"I'm looking for companies that have high-quality growth estimations that are not being considered by the market. So that means prices are not being affected as we believe they should be,\" she says.And she says a lot of companies that \"have this behavior are actually investing in technologies and in AI. So I do not search specifically for AI companies, but I do find that a lot of other companies that are overlooked do have AI processes and AI technologies in their backgrounds,\" said Adenis.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2433460047","title":"BRIEF-Latest DB-OTO Results Show Dramatically Improved Hearing To Normal Levels In A Child With Profound Genetic Deafness Within 24 Weeks And Initial Hearing Improvements In A Second Child At 6 Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2433460047","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2433460047?lang=en_us&edition=fundamental","pubTime":"2024-05-08 18:41","pubTimestamp":1715164913,"startTime":"0","endTime":"0","summary":"May 8  - Regeneron Pharmaceuticals Inc :   * LATEST DB-OTO RESULTS SHOW DRAMATICALLY IMPROVED HEARING TO NORMAL LEVELS IN A CHILD WITH PROFOUND GENETIC DEAFNESS WITHIN 24 WEEKS AND INITIAL HEARING IMPROVEMENTS IN A SECOND CHILD AT 6 WEEKS   * REGENERON PHARMACEUTICALS INC: ONGOING PHASE 1/2 CHORD TRIAL IS CURRENTLY ENROLLING INFANTS AND CHILDREN IN U.S., UK AND SPAINSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regeneron.com","stockEarnings":[{"period":"1week","weight":0.0087},{"period":"1month","weight":0.09},{"period":"3month","weight":0.0361},{"period":"6month","weight":0.2241},{"period":"1year","weight":0.3141},{"period":"ytd","weight":0.1184}],"compareEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0577},{"period":"3month","weight":0.0599},{"period":"6month","weight":0.1745},{"period":"1year","weight":0.2629},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.041845},{"month":2,"riseRate":0.393939,"avgChangeRate":0.089316},{"month":3,"riseRate":0.484848,"avgChangeRate":-0.042863},{"month":4,"riseRate":0.484848,"avgChangeRate":0.019407},{"month":5,"riseRate":0.647059,"avgChangeRate":0.064569},{"month":6,"riseRate":0.393939,"avgChangeRate":0.002817},{"month":7,"riseRate":0.636364,"avgChangeRate":0.053843},{"month":8,"riseRate":0.515152,"avgChangeRate":0.019343},{"month":9,"riseRate":0.484848,"avgChangeRate":0.029068},{"month":10,"riseRate":0.393939,"avgChangeRate":-0.00018},{"month":11,"riseRate":0.545455,"avgChangeRate":0.046018},{"month":12,"riseRate":0.515152,"avgChangeRate":0.048311}],"exchange":"NASDAQ","name":"Regeneron Pharmaceuticals","nameEN":"Regeneron Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Regeneron Pharmaceuticals(REGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Regeneron Pharmaceuticals,REGN,Regeneron Pharmaceuticals股票,Regeneron Pharmaceuticals股票老虎,Regeneron Pharmaceuticals股票老虎国际,Regeneron Pharmaceuticals行情,Regeneron Pharmaceuticals股票行情,Regeneron Pharmaceuticals股价,Regeneron Pharmaceuticals股市,Regeneron Pharmaceuticals股票价格,Regeneron Pharmaceuticals股票交易,Regeneron Pharmaceuticals股票购买,Regeneron Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Regeneron Pharmaceuticals(REGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction